Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics (NYSE:CLDI) has received a new U.S. patent for its SuperNova technology platform, enhancing its intellectual property and advancing its CLD-201 program.
July 18, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calidi Biotherapeutics has been granted a new U.S. patent for its SuperNova technology platform, which is expected to strengthen its intellectual property portfolio and support the advancement of its CLD-201 program into clinical trials.
The issuance of a new patent for Calidi's SuperNova technology strengthens its intellectual property portfolio, which is crucial for a clinical-stage biotech company. This development is likely to positively impact investor sentiment and support the advancement of its CLD-201 program into clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100